Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for the next decade.
A complete C-to-Miniforth compilation and execution system featuring a retargeted LCC compiler backend and a custom stack-based virtual machine. Miniforth VM Bytecode v1.0 Entry Point: main 0000: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback